Pricing Log in Create free account
Saturday 7 November 2026 Export OSCR’s income statement to Excel — free account

Oscar Health, Inc.

OSCR Healthcare Healthcare Plans

Oscar Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.7 billion, up 27.5% from fiscal 2024.

Revenue
+72.1%
EPS
+201.9%
Free cash flow
−24.5%
Total debt
−37.0%

Quarter to September 2026, against a year earlier

30.65 2.53 −7.63%
Market cap
$10.2B
P/E
11.0×
Fwd P/E
15.9×
Dividend yield
—
F-score
3/9
Altman Z
1.07
Beneish M
−2.18
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Oscar Health, Inc. (OSCR) valuation and DCF model

What the price implies · reverse DCF

At $30.65 the price implies the cash flow shrinking by more than 20% a year.

The industry’s median company is priced for −2.1%.

The headline discounts the last twelve months’ free cash flow after share-based pay at 9.0% for ten years and grows it 2.5% a year after that, the same for every company, so the figure compares across the market (how a reverse DCF works).

The other way round · DCF
Its base case
5.0% a year for five years, then 3.0%
$240.74
685.5% above today’s price

Both are growth in free cash flow after share-based pay, discounted at 9.0%, with 2.5% a year after year ten.

Base case on its own ten-year record Oscar Health, Inc.’s own growth, carried forward

Its assumptions

Powerpack lets you start from a scenario and type over any of them.

The base case’s inputs, which Powerpack lets you change
1 · Cash flow to equity
the four quarters to September 2026, from the 10-Q and 10-K filings, before share-based pay

Yearly growth in cash flow. It usually slows as the company matures.

2 · Rates

Cost of equity is the yearly return shareholders require, typically 8–11%. Terminal growth is growth forever after year 10, usually near long-run inflation, 2–3%.

3 · Per share

Diluted shares outstanding. Net debt, under Advanced inputs, is taken off before dividing.

Advanced inputs
Free cash flow Revenue and margin
negative is net cash
new shares the cash flow does not pay for

Against Oscar Health, Inc.’s own cost of capital: risk-free 4.3% + beta 2.50 × equity premium 4.5% = 15.6% cost of equity; weighted, 15.6%.

Use 15.6%
Equity value $76.56b ▲ above market cap $9.75b
Base case value per share $240.74 equity value ÷ 318.01m shares
Current price $30.65 market price per share
Above today’s price 685.5% upside at the base case’s assumptions

How we got there$32.46b 10 years of cash to equity+$40.06b terminal value+$4.03b net cash=$76.56b equity value÷318.01m shares=$240.74 per share

Valuation against its own history

Today’s multiple against its 5- and 10-year averages and the industry median (Healthcare Plans).

Multiple Current 5Y avg 10Y avg vs 10Y avg Industry median vs industry 10Y range
P/E 11.01× 45.04× 45.04× 76% below 22.50× 51% below
P/FCF 2.29× 3.12× 3.42× 33% below 14.76× 85% below
P/B 4.26× 2.87× 2.56× 66% above 2.77× 54% above
EV/EBITDA 8.60× 13.85× 13.85× 38% below 12.61× 32% below
EV/Sales 0.31× 0.19× 0.34× 10% below 0.36× 14% below
P/E P/FCF P/B EV/EBITDA EV/Sales
0.16×0.33×0.50×0.67×10Y avg 0.34×2019202020212023202420252026

OSCR trades at 0.31× EV/Sales, against a 10-year average of 0.34× (range 0.08×–0.72×). That is dearer than 67% of the last 6 year-end readings; re-rating to the average implies $32.59 per share.

Every growth rate on this page is the business’s — its cash flow, FFO or dividend — never its share price’s. A discounted-cash-flow model is only as good as its assumptions. Figures from the 10-K and 10-Q filings. Not investment advice.